• Control iPSC Differentiated
    Hematopoietic Progenitor Cells &
    Natural Killer Cells
    • High Purity
    Control iPSC Differentiated <br/>Hematopoietic Progenitor Cells & <br/> Natural Killer Cells

iPSC-derived Hematopoietic Progenitor Cells (HPC) & Natural Killer Cells (NK)

Applied StemCell has developed an efficient integration-free, small molecule-based method to
differentiate high-quality hematopoietic progenitor cells (HPC) and natural killer cells (NK) from human iPSCs. The differentiated HPCs and NKs recapitulate the phenotype and functional parameters of primary and in vivo HPCs and NKs. These iPSC-differentiated cells can be used as control lines to compare phenotype and functionality of patient-derived, genome-edited iPSC-derived cells for drug screening applications. These NK and HP cells can also be used as effector cells for cytotoxicity assays.

  • iPSC-derived Hematopoietic Progenitor Cells (HPC)
    Applied StemCell provides high purity iPSC-derived hematopoietic progenitor cells that express high levels of HPC biomarker, CD34.
  • iPSC-derived Natural Killer Cells (NK)
    We also provide high purity iPSC-derived NK cells that express high levels of NK cell biomarkers, CD56 and CD45.
  • Affordable Prices
  • Fast Turn-Around Time

 

FAQs
Can the NK cells undergo proliferation?
Can I order the media provided in the iPSC-Derived Human NK Cell Kit (ASE-9708) separately?
What is the ability of iPSC-derived hematopoietic progenitor cells to proliferate and differentiate into microglia?
How many times can the HPCs be passaged?
Products and Services
Application Notes

Natural Killer (NK) cells are a type of lymphoid cells that originate from the same progenitor as T cells and B cells. They are an important part of the innate immune response. NK cells are activated in response to interferons or macrophage-derived cytokines. They recognize “non-self” cells without the need for antigen presentation or recognition, executing a rapid immune reaction. The broad cytotoxicity and rapid apoptosis induced by the NK cells helps contain virus-infected cells and controlling early signs of cancer while the adaptive immune response is activated to produce cytotoxic T cells to clear the antigens. With the improving success rate of CAR-T cell therapy, scientists are exploring the NK cells to engineer them for CAR-NK cell therapy to target cancer cells. CAR-NK cells have certain advantages over CAR-T cells in that they retain their natural tumor recognition and killing ability; they do not require strict HLA matching and lack the potential to cause graft-versus-host disease (GvHD), they do not have same safety concerns as seen with CAR-T cells such as cytokine release syndrome, and therefore they can be generated from allogenic donors and possibly developed as off-shelf therapeutic products.

However, purification of NK cells from allogenic hosts is critical since residual T and B cells may cause GvHD and other complications. Primary NK cells are difficult to harvest, purify, and transfect/transduce, and result in a heterogeneous population. They are also difficult to standardize due to the heterogeneity in starting material from different donors. As well, the generation of large quantities of highly pure NK cells requires an extended manufacturing process which can compromise recovery of NK cells, their viability and potency. Therefore, iPSC-derived NK cells offer a consistent and renewable starting material to provide standardizable NK cells without the dependency on donors and complex harvesting and purification processes. They offer a method to generate homogenous populations of CD56+ CD45+ NK cells and subsequently to generate CAR-NK cells for targeted allogenic cancer immunotherapy, even solid tumors.

Natural killer cells for cancer immunotherapy: a new CAR is catching up. (). EBioMedicine39, 1–2. doi:10.1016/j.ebiom.2019.01.018.

Zeng, J., Tang, S. Y., Toh, L. L., & Wang, S. (). Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells. Stem cell reports9(6), 1796–1812. doi:10.1016/j.stemcr.2017.10.020.

 

Technical Details

Characterization of the ASE-9718 Hematopoietic Progenitor Cells

 

Figure 1. Flow cytometry analysis of ASE-9718 iPSC-derived Hematopoietic Progenitor Cells for a HPC biomarker. Cryopreserved HPCs, differentiated from Applied StemCell’s control iPSC line, ASE-9211 were recovered in HPC culture basal media. The cells were stained with HPC cell marker, CD34 (right panel) or isotype control (Left panel).

Characterization of the ASE-9708 NK Cells

Figure 2. Flow cytometry analysis of ASE-9708 iPSC-derived NK cells for NK cell biomarkers. Cryopreserved NKs, differentiated from Applied StemCell’s control iPSC line, ASE-9211 were recovered in NK culture media. The cells were stained with NK cell markers, CD45 and CD56 at day 2. Left: Isotype control antibodies. Right: CD45/CD56.

Have Questions?

An Applied StemCell technical expert is happy to help, contact us today!

Google